PharmatrophiX is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. We are advancing a pipeline of small-molecule drugs targeting p75 as well as the TrkB and TrkC receptors designed to prevent fundamental neurodegenerative mechanisms and to promote synaptic resilience.
About UsPharmatrophiX is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. We are advancing a pipeline of small-molecule drugs targeting p75 as well as the TrkB and TrkC receptors designed to prevent fundamental neurodegenerative mechanisms and to promote synaptic resilience.
About UsOver 7 million Americans are living with Alzheimer’s disease today and with a new case diagnosed every 33 seconds, by 2050, this number is projected to rise to nearly 13 million Americans. According to the Alzheimer’s Association, health and long-term care costs for people living with Alzheimer’s, Parkinson’s and other dementias in the U.S. are expected to reach $409 billion in 2026 and $1.1 trillion by 2050.
Americans impacted today, projected to reach nearly 13M by 2050.
A new Alzheimer’s case is diagnosed every 33 seconds.
Annual U.S. spend on dementia care by 2050, up from $384B in 2025.
LM11A-31 is a first-in-class small molecule targeting the p75 neurotrophin receptor. It shifts signaling away from degeneration and toward synaptic protection, offering hope for patients and families.
LM11A-31 modulates p75NTR signaling to shift from degeneration toward neuronal protection and synaptic repair.
After decades of research, American scientists may finally be closing in on new ways to fight Alzheimer’s disease.
Read MoreMeryl Comer talks with Dr. Frank Longo, of PharmatrophiX. Dr. Longo’s work shifts the question from how to clear amyloid…
Read MoreNew imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity.
Read More
